[go: up one dir, main page]

DE69940264D1 - Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 - Google Patents

Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1

Info

Publication number
DE69940264D1
DE69940264D1 DE69940264T DE69940264T DE69940264D1 DE 69940264 D1 DE69940264 D1 DE 69940264D1 DE 69940264 T DE69940264 T DE 69940264T DE 69940264 T DE69940264 T DE 69940264T DE 69940264 D1 DE69940264 D1 DE 69940264D1
Authority
DE
Germany
Prior art keywords
geneva
product
cancer antigen
tumor suppressive
suppressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940264T
Other languages
English (en)
Inventor
Haruo Sugiyama
Yoshihiro Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69940264(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Application granted granted Critical
Publication of DE69940264D1 publication Critical patent/DE69940264D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69940264T 1998-07-31 1999-07-30 Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 Expired - Lifetime DE69940264D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31
PCT/JP1999/004130 WO2000006602A1 (fr) 1998-07-31 1999-07-30 Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1

Publications (1)

Publication Number Publication Date
DE69940264D1 true DE69940264D1 (de) 2009-02-26

Family

ID=16714530

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940264T Expired - Lifetime DE69940264D1 (de) 1998-07-31 1999-07-30 Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1

Country Status (15)

Country Link
US (7) US7030212B1 (de)
EP (3) EP1103564B1 (de)
JP (2) JP4422903B2 (de)
KR (1) KR100767554B1 (de)
CN (4) CN1560078B (de)
AT (1) ATE420112T1 (de)
AU (1) AU4932199A (de)
BR (1) BRPI9912663B8 (de)
CA (1) CA2337743C (de)
DE (1) DE69940264D1 (de)
DK (1) DK1103564T3 (de)
ES (1) ES2318898T3 (de)
HK (1) HK1038929B (de)
PT (1) PT1103564E (de)
WO (1) WO2000006602A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
BR9914116A (pt) * 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
ATE494905T1 (de) * 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
EP1548028B1 (de) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituierte wt1-peptide
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
PL2071028T3 (pl) * 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
EP2186896B1 (de) * 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Von WT1 abgeleitete Krebs-Antigenpeptide
EP2565201B1 (de) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1-HLA-Klasse II-bindende Peptide und Zusammensetzungen und Verfahren damit
RU2424247C2 (ru) * 2005-11-30 2011-07-20 Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка
EP3117836A1 (de) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verwendungen davon
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
EP2127671B1 (de) 2007-02-07 2016-09-14 Nec Corporation Therapeutisches krebsmittel
ES2559062T3 (es) 2007-02-27 2016-02-10 International Institute Of Cancer Immunology, Inc. Método para la activación de linfocitos T colaboradores y composición para su uso en el método
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
KR101610664B1 (ko) * 2007-12-05 2016-04-08 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 백신 조성물
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
EP2792745B1 (de) * 2011-12-14 2017-11-15 National University Corporation Kochi University Modifizierung eines helfer-t-zellen-induzierenden polypeptids
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
ES2655031T3 (es) * 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
KR102158225B1 (ko) 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
KR20140099828A (ko) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 점막 투여용 백신 조성물
IN2014CH00393A (de) * 2013-02-05 2015-04-03 Nitto Denko Corp
EP2762155B1 (de) 2013-02-05 2020-03-11 Nitto Denko Corporation Impfstoffzusammensetzung
KR20140100417A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
JP6497691B2 (ja) 2013-02-05 2019-04-10 日東電工株式会社 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
CN103961698A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
JP6712261B2 (ja) 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
EP3199175B1 (de) 2014-09-27 2022-03-23 Sumitomo Dainippon Pharma Co., Ltd. Pharmazeutische zusammensetzung zur injektion
JP6947720B2 (ja) * 2015-09-10 2021-10-13 メモリアル スローン ケタリング キャンサー センター Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法
CN116327902A (zh) 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
CN109069599A (zh) * 2016-03-03 2018-12-21 法国古士塔柏罗斯学院 针对癌症的基于ptp的疫苗
EP3549957A4 (de) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1-helferpeptid und kombination des besagten peptids und eines krebsantigen-peptidkonjugats
US20210100886A1 (en) 2017-03-30 2021-04-08 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
WO2020067453A1 (ja) 2018-09-28 2020-04-02 大日本住友製薬株式会社 注射用組成物
MX2021003938A (es) * 2018-10-05 2021-08-11 Int Inst Cancer Immunology Inc Composicion para prevenir o tratar un tumor benigno.
TW202528332A (zh) 2019-02-28 2025-07-16 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
US12448430B2 (en) 2019-03-11 2025-10-21 Fred Hutchinson Cancer Center High avidity WT1 T cell receptors and uses thereof
EP4017872A1 (de) 2019-08-20 2022-06-29 Fred Hutchinson Cancer Center Wt-1-spezifische t-zell-immuntherapie
EP4085130A4 (de) 2019-12-31 2024-04-10 Elixirgen Therapeutics, Inc. Temperaturbasierte transiente abgabe von nukleinsäuren und proteinen an zellen und gewebe
EP4149534A4 (de) * 2020-05-12 2024-09-04 Cue Biopharma, Inc. Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon
TW202200188A (zh) 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 用以處置癌症之醫藥組合物
CN118076382A (zh) 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JP2546254B2 (ja) 1987-02-23 1996-10-23 澁谷工業株式会社 ガス詰め充填装置
EP0453560B1 (de) 1989-11-13 1999-05-26 Massachusetts Institute Of Technology Lokalisation und charakterisierung des wilms-tumor-gens
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5731160A (en) 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
JPH09506866A (ja) 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
EP0772619B2 (de) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatorische oligonukleotide
AU5779696A (en) 1995-06-01 1996-12-18 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1)
JP3904260B2 (ja) 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
DE59611362D1 (de) 1995-09-19 2006-08-17 Bayer Bioscience Gmbh Pflanzen, die eine modifizierte stärke synthetisieren, verfahren zu ihrer herstellung sowie modifizierte stärke
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
PT1103564E (pt) 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
BR9914116A (pt) 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU760574B2 (en) 1999-01-12 2003-05-15 Smithkline Beecham Biologicals (Sa) Novel treatment
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
ATE320266T1 (de) 1999-07-22 2006-04-15 Dainippon Sumitomo Pharma Co Induktion von antigen-spezifischen t-zellen durch interferon
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
EP1548028B1 (de) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituierte wt1-peptide
ES2332590T3 (es) 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
EP2186896B1 (de) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Von WT1 abgeleitete Krebs-Antigenpeptide

Also Published As

Publication number Publication date
CN102198266A (zh) 2011-09-28
BRPI9912663A (pt) 2001-05-02
JP5230579B2 (ja) 2013-07-10
WO2000006602A1 (fr) 2000-02-10
JP4422903B2 (ja) 2010-03-03
US20160243209A1 (en) 2016-08-25
US7030212B1 (en) 2006-04-18
CA2337743A1 (en) 2000-02-10
US9403886B2 (en) 2016-08-02
EP2280031A1 (de) 2011-02-02
KR20010072112A (ko) 2001-07-31
EP1103564A4 (de) 2005-02-02
CN100560130C (zh) 2009-11-18
HK1038929A1 (en) 2002-04-04
US7807792B2 (en) 2010-10-05
US7517950B2 (en) 2009-04-14
US20060093615A1 (en) 2006-05-04
JP2010059172A (ja) 2010-03-18
ES2318898T3 (es) 2009-05-01
DK1103564T3 (da) 2009-05-11
ATE420112T1 (de) 2009-01-15
HK1038929B (zh) 2005-05-06
CN1178956C (zh) 2004-12-08
CA2337743C (en) 2015-07-07
US20090281043A1 (en) 2009-11-12
HK1130069A1 (en) 2009-12-18
EP1103564A1 (de) 2001-05-30
US7390871B2 (en) 2008-06-24
US20090143291A1 (en) 2009-06-04
CN1314916A (zh) 2001-09-26
HK1036073A1 (en) 2001-12-21
HK1153761A1 (en) 2012-04-05
EP2048160B1 (de) 2015-01-07
AU4932199A (en) 2000-02-21
CN1560078A (zh) 2005-01-05
BRPI9912663B8 (pt) 2021-07-06
EP2280031B1 (de) 2015-04-15
US7608685B1 (en) 2009-10-27
EP1103564B1 (de) 2009-01-07
KR100767554B1 (ko) 2007-10-17
CN1560078B (zh) 2011-06-22
EP2048160A1 (de) 2009-04-15
PT1103564E (pt) 2009-03-13
BRPI9912663B1 (pt) 2011-05-31
CN1762490A (zh) 2006-04-26
US20050266014A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
DE69940264D1 (de) Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
DK1627880T3 (da) Boronester og -syreforbindelser samt syntese og anvendelser
FI931109L (fi) Peptider och nukleinsyrasekvenser, som haenfoer sig till epstein-barr-virus
FI964808A0 (fi) Puhdistetut Myceliophthora lakkaasit ja niitä koodaavat nukleiinihapot
DK0817851T5 (da) DNA, der koder for humant papillomvirus type 18
BR8008756A (pt) Tecnica de reconhecimento de caracteres de multiplas fontes
DE59006562D1 (de) Endoskop, insbesondere Resektoskop.
ZA200000370B (en) Novel antigenic class of avian reoviruses.
FI970071A7 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuum orihyljintäantigeeniä
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
PT1005532E (pt) Moleculas de acido nucleico isoladas que codificam para membros da familia ssx e suas utilizacoes
FI890857L (fi) Skaopenhet att placeras under arbetsbord, i synnerhet diskbord, i ett koek.
ID27733A (id) Metoksiminofenilasetamida
BR0103900A (pt) Processos para a preparação de piranos substituìdos
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
IT1277414B1 (it) Uso di macromolecole di tipo dendrimerico come catalizzatori o coadiuvanti delle reazioni in condizioni di trasferimento di fase
SU884130A1 (ru) Многоканальный функциональный преобразователь аналог-код
ITVI940084A0 (it) Impilatore per prodotti laminari flessibili, particolarmente per pellied affini.
Na et al. Similarity analyses of partial differential equations by the multiparameter Lie group: technical report
NO901640L (no) Forkalibrert, elektrokjemisk foeleanordning for engangsbruk.
IT1256078B (it) Ligandi kit solubili
ITTO940044A0 (it) Dispositivo di interfaccia per sagnalatori, luminosi del tipo led.
CY1112454T1 (el) Ανασυνδυασμενη καρβοξυπεπτιδαση β
IT1293257B1 (it) Apparato ortodontico di trazione extra orale, di tipo composito.

Legal Events

Date Code Title Description
8363 Opposition against the patent